Why Men Should be Screened for the ‘Breast Cancer Gene’ https://lnkd.in/giV6h6eW New research shows that men can carry mutations in the BRCA1 and BRCA2 genes that increase their risk of several cancers, but new national guidelines are helping to educate patients. Newly developed guidelines offer hope for identifying the cancer risk of BRCA mutations in men through genetic testing and tailored cancer screening, according to an article published in JAMA Oncology. Identification of genetic risks can lead to tailored screening, finding cancers earlier and thus improve their chances for better cancer treatment outcomes. Male carriers of BRCA1/2 mutations are at higher risk of prostate, pancreatic, breast and other cancers over the course of their lifetimes. The post Why Men Should be Screened for the ‘Breast Cancer Gene’ appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Washington Oregon Biotech Networks’ Post
More Relevant Posts
-
Breakthrough in Breast Cancer Risk Assessment Researchers have made a significant discovery in assessing breast cancer risk for individuals with BRCA mutations. Key findings: - Normal breast tissue can harbor hidden cancer-causing genetic mutations - These mutations can be detected through genome profiling - A new "clonality score" can evaluate cancer risk in high-risk individuals Implications: - Potential for early intervention and preventive measures - Improved breast cancer risk assessment for BRCA mutation carriers - Enhanced understanding of cancer development https://lnkd.in/gRx-jPZS
-
-
Prostate cancer remains a significant health challenge, with an estimated 1 in 8 men diagnosed during their lifetime. A comprehensive assessment of genetic risk in #prostate cancer should include, along with the monogenic risk in specific #genes (e.g., BRCA1 and BRCA2), an estimation of #PolygenicRisk. Research has shown a significantly higher risk of prostate #cancer in men with mutations (pathogenic variants) in the BRCA2 gene compared to a control group. This finding expands the known range of cancers potentially linked to BRCA1 and BRCA2 beyond breast and ovarian cancers. Targeting these genetic mutations holds promise. Clinical trials exploring PARP inhibitors, a class of drugs that attack cancer cells with faulty DNA repair mechanisms, have shown positive results in patients with BRCA1 and BRCA2 mutations. If you want to learn more, visit this review article in JAMA 👉 https://lnkd.in/dmeg7PSG
-
Today on World Ovarian Cancer Day - we are spotlighting one of our funded researchers! 🔬 Lea Schafer is an Irish Cancer Society and Irish Research Council funded PhD Researcher focusing on ovarian cancer. Many women are diagnosed with ovarian cancer when the disease has already spread, and at some point, some of those women eventually stop responding to their anti-cancer drugs. Lea's work is focused on the role of one specific gene, that changes when tumours become ‘resistant’ to chemotherapy. This suggests that this gene could be one of the reasons why the anti-cancer drugs stop working. Through her work funded by the Irish Cancer Society and the Irish Research Council, Lea is hoping to figure out if this gene could be used as an early warning system for chemo resistance, and if this gene could be one of the reasons why anti-cancer drugs eventually stop working. Lea’s research could help us to better understand how to kill ovarian cancer cells using alternative combinations of anti-cancer drugs. Read more about Irish Cancer Society Research here: https://lnkd.in/euSR5mdQ @IrishResearchCouncil #ThisIsGo #WOCD2024 #NoWomanLeftBehind
-
-
8 May marks World Ovarian Cancer Day. Guardant Health would like to honour all women who are fighting against ovarian cancer. As a precision oncology company, we are doing our best to ensure that no woman is left behind in her fight against cancer. Our liquid biopsy test can detect microsatellite instability-high (MSI-High) and all four classes of genomic variations in clinically relevant genes, out of which, BRCA1, BRCA2, NTRK1 fusion and MSI-High can be found in ovarian cancer. Therapies targeting these gene mutations may be available in your country. Speak to your doctor today about comprehensive genomic testing with a simple blood draw. Visit us at https://lnkd.in/gHNdYtQN to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. #guardanthealthamea #guardanthealth #guardant360 #WorldOvarianCancerDay #WOCD2024 #NoWomanLeftBehind #PowerfulTogether #ovariancancer #liquidbiopsy #genomicprofiling
-
-
#ProGRESS: Current methods of screening men for prostate cancer are inaccurate. They cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS) might help identify which men are at the highest risk for prostate cancer. 🔽
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS): A Pragmatic Trial of Precision Prostate Cancer Screening will examine whether a genetic test helps to identify biological males at risk for significant prostate cancer while helping biological men who are at low risk for prostate cancer to avoid unnecessary biopsies. Did you know prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death? If the genetic test we are studying as part of ProGRESS proves beneficial, it will improve the way that healthcare providers screen biological male Veterans for prostate cancer. We are in the early stages of recruitment and working out the early details of the study. Our goal? To enroll 5,000 Veterans! Study Project Manager Charles Brunette and Study Coordinator Julian Martin are up for the challenge, and we are hopeful that we achieve our study goals! For more information on the ProGRESS Trial, please visit: https://lnkd.in/dDaghs7x
-
-
From: Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme Article Link: https://lnkd.in/gnKW7VBU
Fig. 4: Somatic and germline alterations across common tumor types.
nature.com
-
Medical Strategy, Medical Affairs, and Product Launches ||| Systemic Organisational Constellations ||| Europe, EMEA + Asia.
Identifying proteomic risk factors for cancer ....................... ..........using prospective and exome analyses of 1463 circulating proteins and risk of 19 cancers in the UK Biobank Solid advancements: "In conclusion, we discovered multiple associations between blood proteins and cancer risk. Many of these were detectable more than seven years before cancer diagnosis and had concordant evidence from genetic analyses, suggesting they may have a role in cancer development. We also identified proteins that may mark early cancer processes among carriers of established cancer risk variants, which may serve as potential biomarkers for risk stratification and early diagnosis." https://lnkd.in/eHhHMqjW
-
-
🔬 Exciting advancements in cancer care! AGTC Genomics CancerRisk Hereditary Cancer NGS Test is now including comprehensive #germline genetic testing panels that comply with the latest ASCO guidelines. Our tests cover all the recommended genes for patients with cancer, ensuring a thorough evaluation to identify inherited causes. 🧬 The selection of genes for our panels is backed by a systematic review from an ASCO Expert Panel, which delved into guidelines, consensus statements, and clinical studies. Our approach ensures that the minimum panel includes the most crucial genes, with the option to expand based on individual patient needs and family history. 💡 Why is this important? These panels not only help in understanding the genetic basis of cancer in patients but also guide targeted treatment options. By offering tests that are inclusive of both strongly and less strongly recommended genes, we ensure comprehensive care that’s tailored to each patient’s unique situation. 👥 For anyone facing cancer, knowing your genetic makeup can be a game changer in managing your health. AGTC Genomics is committed to providing this essential service, adhering to the highest standards set by international guidelines.
-
New!🌈 The TP53-activated #E3ligase RNF144B is a tumour suppressor that prevents #genomicinstability ---------------- TP53, the most frequently mutated gene in human cancers, orchestrates a complex transcriptional program crucial for cancer prevention. While certain TP53-dependent genes have been extensively studied, others, like the recently identified RNF144B, remained poorly understood. This E3 ubiquitin ligase has shown potent tumor suppressor activity in murine Eμ Myc-driven lymphoma, emphasizing its significance in the TP53 network. However, little is known about its targets and its role in cancer development, requiring further exploration. In this work, Ana Janic et al investigate RNF144B's impact on tumor suppression beyond the hematopoietic compartment in human cancers. Open access🔓 https://lnkd.in/dVEfCcJc #Aneuploidy IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano
-
-
https://lnkd.in/gmvZ8c4E CANCER BIOMARKERS – Co-Analysis of CTCs & ctDNA: Gaining Multi-Dimensional Insights Into Cancer Heterogeneity: Yoon-Tae Kang, PhD, Abiodun Bodunrin, PhD, and Joby Chesnick, PhD, MBA, believe co-analysis of CTC abundance and phenotypic changes together with ctDNA concentration could allow for real-time monitoring of disease progression and reoccurrence, while genetic and epigenetic changes in CTCs and ctDNA mutations over time could provide valuable insights into the effectiveness of therapeutic interventions, as the presence of different somatic mutations may indicate cancer susceptibility or resistance to certain treatments.
-
